Business By Adam Feuerstein Stakes are high as Alnylam awaits results from novel rare disease therapy
Biotech By Meghana Keshavan When a Nobel Prize brings a shower of hype: the roller coaster ride of RNAi
Business By Damian Garde No stranger to gambling, this biotech CEO is going all-in on a first drug approval
